No Result
View All Result
SUBSCRIBE | NO FEES, NO PAYWALLS
MANAGE MY SUBSCRIPTION
NEWSLETTER
Corporate Compliance Insights
  • Home
  • About
    • About CCI
    • Writing for CCI
    • NEW: CCI Press – Book Publishing
    • Advertise With Us
  • Explore Topics
    • See All Articles
    • Compliance
    • Ethics
    • Risk
    • FCPA
    • Governance
    • Fraud
    • Internal Audit
    • HR Compliance
    • Cybersecurity
    • Data Privacy
    • Financial Services
    • Well-Being at Work
    • Leadership and Career
    • Opinion
  • Vendor News
  • Career Connection
  • Events
    • Calendar
    • Submit an Event
  • Library
    • Whitepapers & Reports
    • eBooks
    • CCI Press & Compliance Bookshelf
  • Podcasts
  • Videos
  • Subscribe
  • Home
  • About
    • About CCI
    • Writing for CCI
    • NEW: CCI Press – Book Publishing
    • Advertise With Us
  • Explore Topics
    • See All Articles
    • Compliance
    • Ethics
    • Risk
    • FCPA
    • Governance
    • Fraud
    • Internal Audit
    • HR Compliance
    • Cybersecurity
    • Data Privacy
    • Financial Services
    • Well-Being at Work
    • Leadership and Career
    • Opinion
  • Vendor News
  • Career Connection
  • Events
    • Calendar
    • Submit an Event
  • Library
    • Whitepapers & Reports
    • eBooks
    • CCI Press & Compliance Bookshelf
  • Podcasts
  • Videos
  • Subscribe
No Result
View All Result
Corporate Compliance Insights
Home Featured

Takeaways from the DOJ’s 2019 False Claims Act Report

With Recoveries Topping $3B in 2019, Expect a Similar Crackdown on Fraud in 2020

by Taylor Chenery, Lauren Gaffney and Anna Grizzle
February 24, 2020
in Featured, Fraud
physician in handcuffs

The DOJ recently released its annual report on False Claims Act enforcement, and FCA enforcement shows no signs of slowing. Bass, Berry & Sims’ Taylor Chenery, Lauren Gaffney and Anna Grizzle discuss what the report reveals.

2020 marks the 150th anniversary of the Department of Justice (DOJ), and based on a recently released 2019 report, its FCA enforcement efforts show no signs of slowing, with health care fraud recoveries undoubtedly continuing to make up the bulk of recoveries. Not only with respect to health care fraud, but across all types of FCA enforcement matters, the government remains committed to pursuing individuals, companies and all participants responsible for potential fraudulent schemes, even where those participants may not contract directly with the government or if they are multiple steps removed from the submission of actual claims to the government.

The 2019 enforcement report provides insight into DOJ priorities, including the types of health care and procurement fraud cases it is pursuing and its decreasing reliance on qui tam whistleblowers. Beyond this report, businesses can also ascertain clues about future enforcement activity from pending legislation and DOJ guidance that will impact how businesses tread in 2020.

2019 FCA Enforcement Overview

In 2019, the DOJ obtained more than $3 billion in settlements and judgments from civil cases involving fraud and false claims against the government in fiscal year 2019.

Matters involving the health care industry continued to dominate the majority of FCA recoveries, constituting $2.6 billion of the more than $3 billion in total recoveries. Enforcement matters spanned across the health care industry, including matters involving drug and medical device manufacturers, managed care providers, hospitals, pharmacies, hospice organizations, laboratories and physicians.

Beyond health care, other notable enforcement matters in 2019 related to procurement fraud involving entities that contract directly with the federal government and to other fraud schemes where the government allegedly suffered harm due to false certifications or representations, particularly by entities that received federal benefits.

Whistleblowers filed 633 qui tam suits in fiscal year 2019 (an average of 12 per week), and the DOJ recovered over $2.1 billion in those and earlier filed suits. Roughly 70 percent of all settlements and judgments reported by the government in fiscal year 2019 arose from lawsuits filed under the qui tam provisions of the False Claims Act (FCA). During that same period, the government paid out $265 million to the whistleblowers who filed those actions – the lowest total amount rewarded to whistleblowers since 2009.

Health Care Fraud

2019 marked the 10th consecutive year that civil health care-related settlements and judgments exceeded $2 billion, an approximate 5 percent year-over-year increase following a 10-year low in 2018. The DOJ also noted in its announcement that the $2.6 billion figure does not reflect the additional millions of dollars that were recovered for state Medicaid programs.

The top recoveries in 2019 stemmed from matters involving drug manufacturers. Reckitt Benckiser Group PLC (RB) agreed to pay $1.4 billion to resolve alleged criminal and civil liability related to allegations that it misrepresented facts relating to the safety and diversion risk of Suboxone film, a drug used to treat drug dependence. Insys Therapeutics agreed to a settlement of $225 million consisting of a $195 million payment to settle FCA allegations, plus an additional $2 million in fines and the forfeiture of $28 million to settle criminal and civil claims that it engaged in illegal marketing tactics and paid kickbacks to health care providers in an effort to promote Subsys, its fentanyl painkiller spray. The government recovered more than $95 million from Avanir Pharmaceuticals over allegations it paid kickbacks and leveraged false and misleading marketing to persuade long-term care providers to prescribe a drug for behaviors commonly associated with dementia, which allegedly was not an approved use for the drug.

The DOJ also continued to investigate drug manufacturers and their role in funding co-payments of Medicare patients. In 2019, a total of $624 million was paid across seven drug manufacturers to resolve allegations that they illegally paid patient copays for their own drugs through independent foundations. The DOJ also highlighted recoveries related to a pathology lab company, an electronic health record vendor and an inpatient rehabilitation provider.

The DOJ reiterated its commitment to using the FCA and other civil remedies to “deter and redress fraud” by both individuals and corporations, highlighting cases in which separate actions and settlements were brought against chief executive officers, health care operators, owners and even a private equity firm that invested in a health care company.

For example, the DOJ obtained a $21 million settlement involving a private equity fund where the government alleged that the fund knew about and approved marketing activities for one of its portfolio companies that allegedly violated the Anti-Kickback Statute. The portfolio company, Diabetic Care Rx, LLC, and two executives also were included in this settlement. The government’s press release for this case explained that it remains committed to holding all participants responsible and indicated that some of the most significant settlements of the year constituted global resolutions of both civil and criminal claims.

Procurement and Other Fraud

DOJ’s non-health-care FCA enforcement efforts in 2019 involved a variety of matters involving the government’s purchase of goods and services. Those matters spanned numerous industries, from national defense and the United States military to institutions of higher education to government contracts involving environmental regulations.

In relation to national defense and military contracts, five South-Korea-based companies collectively paid over $162 million to resolve allegations that they engaged in anticompetitive conduct targeting contracts to supply fuel to the U.S. military in South Korea, causing the Department of Defense to pay substantially more for fuel supply services than it would have absent the alleged collusion.

Northrop Grumman Systems Corporation paid over $27 million to resolve allegations that it billed the United States Air Force under battlefield communications contracts for labor hours purportedly incurred by individuals stationed in the Middle East who had not actually worked the hours claimed. For $20 million, the majority owner and former CEO of defense contractor ADS, Inc., Luke Hillier, settled allegations that he made false representations to fraudulently secure federal set-aside contracts that were reserved for small businesses and that his company was not eligible to receive.

Institutions of higher education were also subject to FCA enforcement based on federal grants or aid they received. Duke University paid $112.5 million to resolve alleged FCA violations by submitting applications and progress reports to the National Institutes of Health and to the Environmental Protection Agency that contained falsified research on federal grants. By paying $2.5 million, North Greenville University resolved allegations that it submitted false claims to the U.S. Department of Education by compensating a student recruiting company based on the number of students who enrolled in NGU’s programs, in violation of the Higher Education Act’s prohibition on such incentive compensation for institutions that receive federal student aid.

With respect to environmental issues, the government recovered more than $3.5 million from gas marketer B. Charles Rogers (BCR) Gas Ltd. and its owners to resolve allegations that they engaged in a scheme to reduce royalty payments that were due in exchange for their license to remove minerals from federal lands. Another individual who worked with BCR while employed as a gas supply manager at a natural gas distributor paid an additional $800,000 based on his alleged role in the scheme. Omega Protein Corp. and Omega Protein, Inc. paid $1 million to resolve allegations that they by falsely certified compliance with federal environmental laws in order to obtain a federal loan.

The DOJ also announced settlements with entities that were not contracted as directly with the government but nonetheless allegedly caused false claims to be submitted to the government. Aluminum extrusion manufacturer Hydro Extrusion Portland, Inc., formerly known as Sapa Profiles Inc. (SPI), paid $34.6 million for “causing a government contractor to invoice NASA and the Department of Defense’s Missile Defense Agency for aluminum extrusions that did not comply with contract specifications,” according to the DOJ’s report. SPI allegedly altered the results of tests designed to ensure the consistency and reliability of the extrusions and provided the contractor with falsified certifications. For $21.57 million, software development company Informatica LLC resolved allegations that it provided misleading information about its commercial sales practices that was used in contract negotiations with the General Services Administration, which caused the government to be overcharged. Resellers who allegedly received false sales information from Informatica then used that information in negotiations with GSA for government contracts, causing GSA to agree to less favorable pricing and government purchasers to be overcharged.

Looking Further into 2020

While there are no signs of FCA enforcement slowing or any other type of recoveries surpassing the total netted from health care fraud matters, the focus of the enforcement efforts may begin to shift in light of the revisions proposed by Department of Health and Human Services Office of Inspector General (HHS-OIG) and the Centers for Medicare and Medicaid Services to the federal Stark Law and Anti-Kickback Statute. The proposals were issued in late 2019 and would, among other things, add and modify existing key definitions, safe harbors and exceptions – especially those related to value-based care and value-based arrangements. If finalized, these changes could potentially alter the way the government enforces the fraud and abuse laws with the stated goal of moving the health care delivery system from a fee-for-service basis to one that pays for value, quality outcomes and cost efficiency. Final comments were due December 31, 2019, so we would hope to see final rules sometime in 2020.

Based on the HHS-OIG Work Plan and existing matters that have pushed into 2020, it also is likely that we will continue to see settlements and recoveries involving drug distributors and manufacturers, as well as related cases against ancillary providers, such as drug testing laboratories and physician prescribers. The government’s enforcement focus on compound pharmacies is also likely to continue. Based on recent audit activity and findings, the government likely will continue to pursue FCA cases based on violations of health care laws especially for pharmacies, durable medical equipment companies and home health providers.

As noted before, the government remains committed to pursuing all entities responsible for potential fraud. Similarly, it is unclear whether the government will remain focused on private equity investors, but in light of the Diabetes Care Rx matter, private equity funds should take extra caution when determining how involved they get in operational matters related to their portfolio companies.

Finally, the government’s reliance on whistleblowers to bring qui tam suits also will continue. However, the DOJ announcement points out that, during the past year it made “increasing use” of its authority to seek dismissal of qui tam cases to “help prioritize and protect the expenditure of government resources.” In a letter to Senator Chuck Grassley, the DOJ indicated that it has filed motions to dismiss in 45 FCA cases since January 2018, still accounting for less than 4 percent of the 1,170 qui tam suits filed during this timeframe. The U.S. Circuit Courts of Appeals are split on the standard of review for these dismissal motions, so further litigation on this topic is expected in 2020.

With so many changes on the horizon for the health care landscape, health care fraud enforcement in particular will continue to be a fast evolving and expanding area of the law. It will be important to keep up not only with enforcement efforts, but also key regulatory developments that will directly impact the government’s recovery efforts. Other areas, however, should not be overlooked when examining operations; the DOJ’s actions over the past year make clear that the DOJ will be focused on any potential fraud of government contractors across industry sectors.


Tags: DOJFalse Claims Act (FCA)
Previous Post

ProcessUnity Expands Vendor Risk Management Software with New Best Practices Configuration

Next Post

Get to Know Sanction Screening

Taylor Chenery, Lauren Gaffney and Anna Grizzle

Taylor Chenery, Lauren Gaffney and Anna Grizzle

Taylor Chenery is a member at Bass, Berry & Sims PLC. He centers his practice on government compliance and investigations and related litigation, focusing on issues of health care fraud and abuse. He has significant experience representing a wide variety of health care clients in responding to governmental investigations and defending False Claims Act lawsuits. Taylor also has significant experience in complex commercial litigation matters, ranging from class action lawsuits to private arbitrations.

Lauren Gaffney is a member at Bass, Berry & Sims PLC. Lauren analyzes and counsels hospital systems, long-term care providers, physician groups, laboratories and other health care providers on the regulatory requirements and operational impacts related to day-to-day operations, including those related to fraud and abuse. Lauren also focuses on internal investigations, which involve responding to governmental inquiries regarding potential regulatory, compliance and clinical issues. Recognizing that the landscape of health care law is constantly changing, Lauren advises clients on business decisions related to delivering superior patient care within a heavily regulated industry. Her experience includes former positions as operations counsel intern for Hospital Corporation of America (HCA inc.) and as an intern for Vanderbilt University Risk and Insurance Management.
Anna Grizzle is a member at Bass, Berry & Sims PLC. With over 20 years of experience, Anna helps health care clients address enforcement and compliance issues and respond to legal and regulatory violations. With significant experience in defending against statistical sampling and extrapolation and claims denials in Medicare and Medicaid claims audits, Anna also has saved health care companies tens of millions of dollars in potential overpayment demands. She also advises health care companies on regulatory and compliance matters, including transactions involving mergers, acquisitions, joint ventures and dispositions. Representing national hospitals, health systems, hospices, ambulatory surgery centers and a variety of other health care providers, laboratories and DMEPOS suppliers from many industry sectors, Anna’s practice involves government enforcement and compliance; health care fraud and abuse; contracting, regulatory and operational matters; mergers and acquisitions; and health care disputes. Anna’s leadership abilities and visionary judgment make her a go-to advisor in the health care sector. In addition, Anna is certified in healthcare compliance (CHC)®. Having served as a member of the firm’s Executive Committee, Anna is looked to as a trusted leader among her peers.

Related Posts

PW FCPA Enforcement and Anticorruption 2022 Review_f

FCPA Enforcement & Anti-Corruption Developments

by Corporate Compliance Insights
March 30, 2023

The year that was in FCPA & anti-corruption efforts 2022: A Year in Review FCPA Enforcement & Anti-Corruption Developments What’s...

Fox_DOJ Speeches_f

Analysis of Recent DOJ Statements

by Corporate Compliance Insights
March 23, 2023

DOJ leaders provide insight into agency's plans. Analysis of Recent Statements DOJ Shaping the Future of Corporate Criminal Enforcement What’s...

Fox_2023 ECCP Update_f

2023 Evaluation of Corporate Compliance Programs

by Corporate Compliance Insights
March 23, 2023

Keeping up with 2023 changes to DOJ guidelines. Additions, Deletions & Changes From 2020 2023 Evaluation of Corporate Compliance Programs...

safe harbor

What Is Safe in a World Without Antitrust Safe Harbors?

by Fiona Schaeffer and Adam Di Vincenzo
March 22, 2023

A trio of policy statements dating back to 1993 established the concept of safety zones with regard to information exchanges...

Next Post
sanctions text on virtual screen

Get to Know Sanction Screening

Compliance Job Interview Q&A

Jump to a Topic

AML Anti-Bribery Anti-Corruption Artificial Intelligence (AI) Automation Banking Board of Directors Board Risk Oversight Business Continuity Planning California Consumer Privacy Act (CCPA) Code of Conduct Communications Management Corporate Culture COVID-19 Cryptocurrency Culture of Ethics Cybercrime Cyber Risk Data Analytics Data Breach Data Governance DOJ Download Due Diligence Enterprise Risk Management (ERM) ESG FCPA Enforcement Actions Financial Crime Financial Crimes Enforcement Network (FinCEN) GDPR HIPAA Know Your Customer (KYC) Machine Learning Monitoring RegTech Reputation Risk Risk Assessment SEC Social Media Risk Supply Chain Technology Third Party Risk Management Tone at the Top Training Whistleblowing
No Result
View All Result

Privacy Policy

Founded in 2010, CCI is the web’s premier global independent news source for compliance, ethics, risk and information security. 

Got a news tip? Get in touch. Want a weekly round-up in your inbox? Sign up for free. No subscription fees, no paywalls. 

Follow Us

Browse Topics:

  • CCI Press
  • Compliance
  • Compliance Podcasts
  • Cybersecurity
  • Data Privacy
  • eBooks Published by CCI
  • Ethics
  • FCPA
  • Featured
  • Financial Services
  • Fraud
  • Governance
  • GRC Vendor News
  • HR Compliance
  • Internal Audit
  • Leadership and Career
  • On Demand Webinars
  • Opinion
  • Resource Library
  • Risk
  • Uncategorized
  • Videos
  • Webinars
  • Well-Being
  • Whitepapers

© 2022 Corporate Compliance Insights

No Result
View All Result
  • Home
  • About
    • About CCI
    • Writing for CCI
    • NEW: CCI Press – Book Publishing
    • Advertise With Us
  • Explore Topics
    • See All Articles
    • Compliance
    • Ethics
    • Risk
    • FCPA
    • Governance
    • Fraud
    • Internal Audit
    • HR Compliance
    • Cybersecurity
    • Data Privacy
    • Financial Services
    • Well-Being at Work
    • Leadership and Career
    • Opinion
  • Vendor News
  • Career Connection
  • Events
    • Calendar
    • Submit an Event
  • Library
    • Whitepapers & Reports
    • eBooks
    • CCI Press & Compliance Bookshelf
  • Podcasts
  • Videos
  • Subscribe

© 2022 Corporate Compliance Insights

Welcome to CCI. This site uses cookies. Please click OK to accept. Privacy Policy
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT